Edwards Lifesciences Corporation (EW): Price and Financial Metrics
Edwards Lifesciences Corporation (EW)
Today's Latest Price: $85.52 USD
Updated Jan 22 7:00pm
Add EW to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 186 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
EW Stock Summary
- Edwards Lifesciences Corp's market capitalization of $54,365,946,854 is ahead of 95.63% of US-listed equities.
- EW's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,190.3 -- higher than 98.02% of US-listed equities with positive expected earnings growth.
- In terms of volatility of its share price, EW is more volatile than 93.42% of stocks we're observing.
- Stocks that are quantitatively similar to EW, based on their financial statements, market capitalization, and price volatility, are BSX, PHG, ILMN, KLAC, and ADI.
- EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.
EW Stock Price Chart Interactive Chart >
EW Price/Volume Stats
| Current price | $85.52 | 52-week high | $92.08 |
| Prev. close | $87.23 | 52-week low | $51.51 |
| Day low | $85.21 | Volume | 3,278,900 |
| Day high | $87.37 | Avg. volume | 2,535,793 |
| 50-day MA | $86.18 | Dividend yield | N/A |
| 200-day MA | $78.51 | Market Cap | 53.30B |
Edwards Lifesciences Corporation (EW) Company Bio
Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.
EW Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $85.52 | $6.23 | -93% |
Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for EW, they are:
- The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.04%; that's greater than only 19.35% of US stocks we're applying DCF forecasting to.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 7.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -93% |
| 1% | -93% |
| 2% | -93% |
| 3% | -93% |
| 4% | -93% |
| 5% | -93% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EW, try BHC, SRDX, COO, SIGA, and OSMT.
Loading social stream, please wait...